

Association of Genetic Variants and Incident Coronary Heart Disease in Multiethnic Cohorts

The PAGE Study

Nora Franceschini, MD, MPH; Cara Carty, PhD; Petra Bůžková, PhD; Alex P. Reiner, MD, MPH; Tiana Garrett, PhD, MPH; Yi Lin, PhD; Jens-S Vöckler, MS; Lucia A. Hindorff, PhD; Shelley A. Cole, PhD; Eric Boerwinkle, PhD; Dan-Yu Lin, PhD; Ebony Bookman, PhD; Lyle G. Best, MD; Jonathan N. Bella, MD; Charles Eaton, MD; Philip Greenland, MD; Nancy Jenny, PhD; Kari E. North, PhD; Darin Taverna, PhD; Alicia M. Young, MS; Ewa Deelman, PhD; Charles Kooperberg, PhD; Bruce Psaty, MD; Gerardo Heiss, MD, PhD

Background—Genome-wide association studies identified several single nucleotide polymorphisms (SNP) associated with prevalent coronary heart disease (CHD), but less is known of associations with incident CHD. The association of 13 published CHD SNPs was examined in 5 ancestry groups of 4 large US prospective cohorts.

Methods and Results—The analyses included incident coronary events over an average 9.1 to 15.7 follow-up person-years in up to 26 617 white individuals (6626 events), 8018 black individuals (914 events), 1903 Hispanic individuals (113 events), 3669 American Indian individuals (595 events), and 885 Asian/Pacific Islander individuals (66 events). We used Cox proportional hazards models (with additive mode of inheritance) adjusted for age, sex, and ancestry (as needed). Nine loci were statistically associated with incident CHD events in white participants: 9p21 (rs10757278; $P=4.7\times 10^{-41}$), 16q23.1 (rs2549513; $P=0.0004$), 6p24.1 (rs499818; $P=0.0002$), 2q36.3 (rs2943634; $P=6.7\times 10^{-6}$), *MTHFD1L* (rs6922269, $P=5.1\times 10^{-10}$), *APOE* (rs429358; $P=2.7\times 10^{-18}$), *ZNF627* (rs4804611; $P=5.0\times 10^{-8}$), *CXCL12* (rs501120; $P=1.4\times 10^{-6}$) and *LPL* (rs268; $P=2.7\times 10^{-17}$). The 9p21 region showed significant between-study heterogeneity, with larger effects in individuals age 55 years or younger and in women. Inclusion of coronary revascularization procedures among the incident CHD events introduced heterogeneity. The SNPs were not associated with CHD in black participants, and associations varied in other US minorities.

Conclusions—Prospective analyses of white participants replicated several reported cross-sectional CHD-SNP associations. (*Circ Cardiovasc Genet.* 2011;4:661-672.)

Key Words: 9p21 locus ■ incident coronary heart disease ■ genetic polymorphisms

Recent genome-wide association studies (GWAS) identified several single nucleotide polymorphisms (SNP) in genes or regions associated with coronary heart disease (CHD). Most were retrospective case-control comparisons, and little is known about the contribution of these genetic variants to the risk of incident CHD in the general population.

Clinical Perspective on p 672

One of the loci most studied for CHD is the 9p21 region near the *CDKN2A-2B* genes. This 58-kb region, in high linkage disequilibrium (LD) in individuals of European ancestry, overlaps a large noncoding RNA (antisense noncoding

Received March 26, 2011; accepted October 14, 2011.

From the Gillings School of Global Public Health (N.F., T.G., K.E.N., G.H.), University of North Carolina, Chapel Hill, NC; Public Health Sciences (C.C., Y.L., A.M.Y., C.K.), Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Biostatistics (P.B.), University of Washington, Seattle, WA; Department of Epidemiology (A.P.R.), University of Washington, Seattle, WA; University of Southern California (J.-S.V., E.D.), Information Sciences Institutes, Marina Del Rey, CA; Office of Population Genomics (L.A.H., E.B.), NHGRI, NIH, Bethesda, MD; Southwest Foundation for Biomedical Research (S.A.C.), San Antonio, TX; Human Genetics Center (E.B.), University of Texas Health Science Center at Houston, Houston, TX; Department of Biostatistics (D.-Y.L.), Gillings School of Public Health, University of North Carolina, Chapel Hill, NC; Missouri Breaks Industries Research, Inc. (L.G.B.), Timber Lake, SD; Bronx-Lebanon Hospital Center & Albert Einstein College of Medicine (J.N.B.), Bronx, NY; Department of Family Medicine & Community Health (Epidemiology; C.E.), Alpert Medical School, Brown University, Providence, RI; Northwestern University Clinical & Translational Sciences (NUCATS) Institute (P.G.), Chicago, IL; University of Vermont College of Medicine (N.J.), Burlington, VT; UNC Center for Genome Sciences (K.E.N.), Chapel Hill, NC; TGen (D.T.), The Translational Genomics Research Institute, Phoenix, AZ; Cardiovascular Health Research Unit (B.P.), Department of Medicine, University of Washington, Seattle, WA.

The online-only Data Supplement is available at <http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.111.960096/-/DC1>.

Correspondence to Gerardo Heiss, MD, PhD, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC. E-mail gerardo_heiss@unc.edu

© 2011 American Heart Association, Inc.

Circ Cardiovasc Genet is available at <http://circgenetics.ahajournals.org>

DOI: 10.1161/CIRCGENETICS.111.960096

RNA in the *INK* locus [*ANRIL*]), which may contribute to atherosclerosis through regulatory function on the *CDKN2A-2B* genes.¹ In addition to clinical CHD, variants in the 9p21 region (ie, rs10757274 and rs2383206) have shown to have associations with coronary artery calcification,^{2,3} premature atherosclerosis,² ischemic stroke,⁴ heart failure,⁵ peripheral artery disease,⁶ abdominal aortic aneurysm, and intracranial aneurysm⁷ in white populations. Helgadottir et al reported early age of onset effects for CHD for this locus.⁸ A recent meta-analysis of 22 studies including 35 872 cases and 95 837 controls, mostly white individuals, also suggested a larger effect (magnitude of association) of 9p21 variants in studies with earlier age of onset of clinical CHD.⁹ Generalization of the genetic effects of this locus to populations of Asian ancestry was also observed in the latter meta-analysis.

A limited number of prospective studies of CHD have replicated the associations of the 9p21 region with incident CHD in white individuals, such as participants of the Atherosclerosis Risk in Communities (ARIC) study.² However, the associations did not replicate in studies of black individuals, including in the ARIC study participants^{2,10}; although, it must be noted that the number of observations was suboptimal in several of these studies.³ To our knowledge, a meta-analysis of the association of the 9p21 locus with incident CHD in other US minorities has not been performed. We also note that additional loci for CHD have been recently described^{11–13} (*CELSR2/PSRC1*, *MTHFDIL*, *MIA3* among others); these associations have not been replicated in US minorities.

The Population Architecture using Genomics and Epidemiology (PAGE) Study enables a comprehensive analysis of the association of previously validated CHD variants with incident CHD in data from multiple prospective cohort studies, and diverse cultural, ancestral, and socioeconomic settings. We examined whether CHD-related SNPs are associated with incident CHD in individuals of European ancestry in PAGE, and evaluated whether these SNPs are associated with incident CHD in US minorities, specifically in individuals self-identified as black, American Indian, Hispanic, and Asian/Pacific Islanders.

Methods

Population and Definition of CHD Events

The PAGE Study includes 4 large ongoing National Institutes of Health–funded population-based studies or consortia: Epidemiological Architecture for Genes Linked to Environment (EAGLE; based on 3 National Health and Nutrition Examination Surveys,¹⁴ [NHANES]), the Multiethnic Cohort (MEC) study¹⁵, Women's Health Initiative (WHI)¹⁶, and Causal Variants Across the Life Course (CALiCo), a consortium of 5 cohort studies: Atherosclerosis Risk in Communities (ARIC),¹⁷ Coronary Artery Risk in Young Adults (CARDIA),¹⁸ Cardiovascular Health Study (CHS),¹⁹ Hispanic Community Health Study/Study of Latinos (HCHS/SOL), and Strong Heart Study (SHS).^{20,21} This report is based on prospective data on incident CHD from the ARIC, CHS, SHS, and WHI studies. Fatal and nonfatal incident CHD events were defined as acute myocardial infarction (MI), fatal CHD, ECG diagnosis of MI (except in the WHI), and/or documented coronary revascularization procedures, based on record abstraction and confirmed by a panel of

physician reviewers. Prevalent cases of CHD at the respective baseline visits were excluded.

The design of the parent studies has been previously described. Briefly, the ARIC study is a multicenter prospective investigation of atherosclerotic disease in a biracial population (white and black).¹⁷ ARIC recruited 15 792 individuals age 45 to 64 years from 4 communities for a baseline examination in 1987 to 1989, with follow-up examinations in approximate 3-year intervals: during 1990 to 1992, 1993 to 1995, and 1996 to 1998. CHD events were ascertained from annual follow-up morbidity and mortality surveillance, including hospitalizations and deaths. Events were reviewed by 2 physicians, and differences were adjudicated. CHD events were defined as nonfatal acute (definitive or probable) MI, fatal CHD, and coronary revascularization procedures (coronary angioplasty or coronary artery bypass graft) through December 31, 2005. All subjects provided written informed consent. CHS is a population-based cohort study of risk factors for CHD and stroke in adults age ≥ 65 years conducted across 4 field centers in the United States.¹⁹ The original, predominantly white cohort of 5201 persons was recruited in 1989 to 1990 from a random sample of people on Medicare eligibility lists; also, 687 black individuals were enrolled subsequently in 1991 to 1992 for a total sample of 5888 individuals. CHS participants completed standardized clinical examinations and questionnaires at study baseline and during 9 annual follow-up visits. Follow-up for clinical events occurred every 6 months. CHD was classified by the CHS end points committee; suspected events were investigated further by a physician review panel. CHD events were defined as nonfatal MI, coronary artery angioplasty, coronary bypass surgery, or cardiovascular disease (CVD) death caused by atherosclerotic CHD. CHD follow-up was available through June 30, 2007. SHS recruited 4549 American Indian subjects age 45 to 74 years from 1989 to 1992 from 13 tribes at 3 study centers: Oklahoma, North and South Dakota, and Arizona.²⁰ Events were determined from medical records, autopsy reports, and informant interviews; all materials were independently reviewed by physician members of the SHS study's morbidity and mortality committees. CHD events were defined by the occurrence of nonfatal definite MI, definite CHD, ECG-evident definite MI, fatal definite MI, definite CHD, and sudden death. Follow-up went from 1989 to 1991 through December 31, 2006. The Indian Health Service Institutional Review Board and institutional review boards of the participating institutions and participating tribes approved the study; informed consent was obtained from all participants. WHI is a prospective cohort study investigating postmenopausal women's health in the US.¹⁶ A total of 161 838 women age 50 to 79 years old were recruited from 40 US clinical centers between 1993 and 1998 to participate in the observational study and in clinical trials: postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary modification trial.¹⁶ Study protocols and consent forms were approved by the institutional review boards at all participating institutions. Annual (observational studies) and semiannual (clinical trials) follow-up identifies self-reported events, which are then adjudicated following medical record review.²² CHD was defined as acute (definitive or probable) MI requiring overnight hospitalization, fatal CHD, or coronary revascularization (coronary angioplasty or coronary artery bypass graft) procedures. Acute MI was determined according to standardized criteria that included cardiac pain, cardiac enzyme (and troponin levels), and ECG readings. Events as of August 2009 are included in these analyses. A subset of 21 000 WHI women was selected for genotyping and for inclusion in the current study. Women were selected based on self-reported history of disease, incident event outcomes, DNA availability and consent, and racial/ethnic diversity. Follow-up was through August 2009.

SNP Selection and Genotyping

SNPs (in genes or regions) were identified from published GWAS for their association with CHD, and those available as per January 2009 were genotyped in PAGE studies.^{23–28} SNPs were available in at least 1 study for the following loci: the 9p21 region near the

CDKN2A-2B gene (rs1333049, rs2383207, rs10757274), *CELSR2/PSRC1/SORT1* (rs599839), *SMAD3* (rs17228212), 6p24.1 (rs499818), 16q23.1 (rs2549513), *MIA3* (rs17465637), *MTHFD1L* (rs6922269), 2q36.3 (rs2943634), *APOE* (rs429358, rs7412), *ZNF627* (rs4804611), *CXCL12* (rs501120), *LPL* (rs268), and *PCSK9* (rs11206510). We examined the correlation among SNPs in the same region using pair-wise r^2 and D' statistics²⁹ for linkage disequilibrium (LD). For 3 SNPs located in the 9p21 region (rs10757278, rs1333049, rs2383207) in black subjects (ARIC) and in American Indian subjects (SHS), the correlation among SNPs was 0.85 or more in blacks and in American Indians (online-only Data supplement Figure S1A-D, <http://stroke.ahajournals.org>). Therefore, we only reported associations for 1 SNP in the region (rs10757278). For the 2 *APOE* SNPs, correlation was 0.99 in all ethnicities, and therefore we reported only associations for rs429358.

Genotyping was performed in 2 centers: the CALiCo Core Genotyping Laboratory at Human Genetics Center at The University of Texas (Houston, TX) genotyped samples from ARIC, CHS, and SHS using Taqman assays (Applied Biosystems); the Translational Genomics Research Institute (Phoenix, AZ) genotyped WHI samples using Illumina's Veracode GoldenGate genotyping assays. Each laboratory genotyped 360 HapMap samples for cross-laboratory and cross-platform quality control. Quality control assessments included sample call rates (>95%), concordance of blinded replicates (>98%), and deviation from Hardy-Weinberg equilibrium among controls within self-reported ethnic group ($P < 0.01$). In CALiCo populations with previous GWAS characterization (ARIC and CHS), genotyped SNPs were used (Affymetrix 6.0 for ARIC and Illumina Human 370CNV BeadChip) in CHS.³⁰ Quality control for GWAS has been described.³⁰ All alleles were aligned to positive strands.

Statistical Analysis

All analyses were stratified by study and self-reported ethnicity. Cox proportional hazard models (implemented in SAS 9.2 using PROC PHREG procedure or in R)³¹ were used to estimate ethnic-specific associations of SNPs with CHD (hazard ratios [HR] and 95% confidence intervals) while adjusting for baseline levels of covariates age and sex, study site (as applicable) and population stratification. We also performed an analysis adjusting for body mass index, ever smoking, type 2 diabetes, systolic blood pressure, blood pressure-lowering medication use and education (12 years or equivalent versus <12 years). Results were unchanged in fully adjusted models and therefore we report minimally adjusted models except for 9p21 region in white subjects. Lipid measures were only available in a subset of women in the WHI and therefore were not included in analyses. To explore phenotypic heterogeneity as described by Kitsios et al,³² we also performed sensitivity analyses using an alternative CHD definition that included only fatal CHD and nonfatal MI.

PAGE studies used the following strategies to adjust for population stratification: ARIC white individuals and WHI used principal components estimated from preexisting GWAS data, adjusting only for PCs significantly associated with the outcome ($\alpha = 0.05$). For ARIC black individuals, a set of 1536 ancestry informative markers genotyped among 3965 black ARIC participants was used to derive mean percentage of European ancestry using the software ANCESTRYMAP.³³ This variable was included as a covariate in the regression analyses. SHS used self-reported percentage of Indian blood.

All analyses used additive genetic models as described in the initial publications for these SNPs and/or the replication studies in white participants. WHI used weighted analyses to account for the sampling schema, with sample weights ranging from 1 to 60.4. The study-specific log (HR) estimates were combined within each ethnicity using inverse-weighted variance meta-analyses.³⁴ Summary estimates and 95% CI are reported. A nominal replication was considered a probability value < 0.05 and a Bonferroni adjusted replication was considered probability value < 0.0008 (13 SNPs and 5 ethnicities for $\alpha = 0.05$). We also tested for evidence of between-study heterogeneity³⁵ by estimating the between-study variance and the I^2 metric, which is a measure of the percentage of the total variation across studies caused by heterogeneity

rather than chance.³⁶ For the 9p21 SNP association, which showed significant between-study heterogeneity ($P < 0.10$), we performed stratified analyses by age and sex.

We also constructed an additive genetic risk score (0–18 alleles) comprising the number of risk alleles at the 9 loci showing significant replication in white individuals ($P < 0.0008$); we used data from the following SNPs (coded allele): rs10757278 (G), rs2549513 (A), rs499818 (A), rs6922269 (A), rs429358 (C), rs4804611 (A), rs501120 (T), rs268 (G), and rs2943634 (C). We then tested the association of categories or continuous risk scores with incident CHD in WHI, the study that had data on all the SNPs.

For associations in samples of US minorities, we estimated power assuming an additive genetic effect, magnitude of effect estimate of reported associations in white individuals, an $\alpha = 0.05$, a 2-sided test, and population baseline prevalence of 0.10 (Quanto v.1.2.4).

Results

Associations with incident CHD events were examined in the prospective cohorts of white individuals (up to 26 617 individuals and 6626 events), black individuals (8018 individuals and 914 events), Hispanic individuals (1903 individuals and 113 events), American Indian individuals (3669 individuals and 595 events) and Asian/Pacific Islander individuals (885 individuals and 66 events). The mean follow-up of studies varied from 9.1 to 15.7 person-years (online-only Data Supplement Table I). CHS participants were older than were individuals in other studies, and WHI recruited only women (Table 1). CHD risk factors varied across studies and ethnicities.

We first evaluated replication of SNP associations with incident CHD in samples of white individuals. Nine of 13 investigated loci associations showed replication by our a priori criteria ($P < 0.0008$) including the 9p21 region (Table 2), 16q23.1 (rs2549513; $P = 0.0004$), 6p24.1 (rs499818; $P = 0.0002$), *MTHFD1L* (rs6922269; $P = 5.1 \times 10^{-10}$), 2q26.3 (rs2943634; $P = 6.7 \times 10^{-6}$), *APOE* (rs429358; $P = 2.7 \times 10^{-18}$), *ZNF627* (rs4804611; $P = 5.0 \times 10^{-8}$), *CXCL12* (rs501120; $P = 1.4 \times 10^{-6}$) and *LPL* (rs268; $P = 2.7 \times 10^{-17}$; Table 3). Meta-analyses including incident findings from published variants in the ARIC study are shown in online-only Data Supplement Table II. Replicated loci had similar direction and magnitude of effects as reported. Using an additive genetic score from these 9 SNPs, we observed an increased hazard of CHD across increasing categories of genetic risk score (Table 4). *CELSR2/SORT*, *MIA3*, and *SMAD3* SNPs were not associated with incident events in white individuals.

In the 9p21 region, the proxy SNP rs10757278 had associations of similar direction and magnitude as in published studies, but we noted significant between-study heterogeneity at this locus (Table 2). Each copy of the rs10757278 G allele was associated with increased hazard of CHD that varied from 10% (CHS) to 22% (WHI; P for heterogeneity = 0.03; $I^2 = 71.5\%$). Study-specific cumulative incidence findings by genotypes are shown in online-only Data Supplement Table III. Estimates were unchanged in analyses adjusted for multiple CHD risk factors (Table 2). Sex-specificity and the varying age at recruitment were investigated as possible sources of the heterogeneity of effects. The hazard ratios for CHD by decade of age at study recruitment summarized in Figure A show a notably greater risk of CHD for individuals age 55 years or younger. The magnitude of the risk estimates decreased with increasing decade of age,

Table 1. Study Characteristics by Self-Reported Race/Ethnicity

Studies Race	ARIC			CHS				Strong Heart Study American Indian				WHI*				
	White	Black	Black	White	Black	Black	Dakotas	Arizona	Oklahoma	White	Black	Hispanic	American Indian	Hispanic	American Indian	Asian-Pacific Islander
No.	10 247	3943	837	4313	837	837	1186	1170	1124	12 410	3972	1905	203	1905	203	886
Mean Age (SD), y	54.2 (5.7)	53.4 (5.8)	72.9 (5.8)	72.7 (5.6)	72.9 (5.8)	72.9 (5.8)	56.4 (8.1)	55.7 (7.9)	56.7 (8.3)	66.9 (6.9)	61.3 (7.1)	60.2 (6.6)	61.3 (7.5)	60.2 (6.6)	61.3 (7.5)	64.1 (7.5)
Male, %	45.4	37.5	36.7	40.0	36.7	36.7	42.1	35.9	40.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Education <12 y, %	16.3	41.3	45.2	26.1	45.2	45.2	52.5	61.9	30.8	4.5	12.2	27.8	18.2	27.8	18.2	5.9
Mean BMI (SD), kg/m ²	26.9 (4.9)	29.6 (6.1)	28.5 (5.6)	26.3 (4.5)	28.5 (5.6)	28.5 (5.6)	29.3 (5.4)	32.5 (7.2)	30.8 (6.0)	28.8 (6.7)	33.1 (7.8)	30.6 (7.0)	30.5 (6.4)	30.6 (7.0)	30.5 (6.4)	25.5 (4.6)
Hypertension†, %	26.0	55.3	72.9	55.4	72.9	72.9	29.6	43.8	43.5	46.3	55.6	33.0	43.4	33.0	43.4	50.7
Diabetes mellitus‡, %	8.4	19.2	8.2	7.1	8.2	8.2	32.7	64.3	36.1	2.7	4.9	2.9	9.4	2.9	9.4	4.4
Mean SBP (SD), mm Hg	118.3 (16.9)	128.7 (21.2)	141.9 (23.0)	135.8 (21.4)	141.9 (23.0)	141.9 (23.0)	122.9 (18.5)	130.9 (20.7)	128.8 (18.5)	131.9 (18.4)	132.3 (17.4)	126.9 (17)	128.5 (17.5)	126.9 (17)	128.5 (17.5)	132.9 (18.6)
Mean DBP (SD), mm Hg	71.6 (10.0)	79.7 (12.1)	75.2 (11.3)	70.2 (11.2)	75.2 (11.3)	75.2 (11.3)	75.3 (10.3)	77.7 (9.8)	77.2 (10.1)	75.3 (9.5)	78.5 (9.6)	75.7 (9.3)	76.2 (8.6)	75.7 (9.3)	76.2 (8.6)	78.7 (9.4)
Mean LDL cholesterol§, (SD), mg/dl	136.8 (37.6)	137.5 (43.1)	128.9 (36.6)	130.0 (35.5)	128.9 (36.6)	128.9 (36.6)	125.6 (33.2)	104.3 (32.4)	119.9 (32.2)	132.5 (34.3)	134.4 (39.3)	128.4 (34.9)	124.8 (37.6)	128.4 (34.9)	124.8 (37.6)	121.8 (32.3)
Mean HDL cholesterol§, (SD), mg/dl	51.0 (16.8)	55.3 (43.1)	57.9 (15.3)	54.6 (15.8)	57.9 (15.3)	57.9 (15.3)	46.9 (14.7)	44.8 (12.8)	46.6 (13.9)	58.6 (15.6)	57.6 (15.2)	54.0 (14.5)	52.6 (13.4)	54.0 (14.5)	52.6 (13.4)	59.2 (15.8)
Ever smoking	59.0	53.1	51.6	52.4	51.6	51.6	78.2	57.2	68.9	50.2	50.1	37.4	50.7	37.4	50.7	28.1
Anti-hypertensive drugs, %	18.6	39.7	60.8	40.8	60.8	60.8	16.4	26.4	26.6	30.1	43.6	21.3	30.1	21.3	30.1	35.3
Lipid-lowering drugs, %	3.0	1.2	6.1	4.5	6.1	6.1	0.3	0.0	0.8	8.7	7.0	6.3	6.9	6.3	6.9	17.2

ARIC indicates Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; WHI, Women's Health Initiative; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

*WHI results are from unweighted data.

†SBP \geq 140 mm Hg, DBP \geq 90 mm Hg or self-reported use of anti-hypertensive medications.

‡Fasting blood glucose level \geq 7 mmol/L after a 8-h fasting period or the self-reported use of oral hyperglycemic medication or insulin.

§LDL cholesterol was available in 5056 WHI women and HDL cholesterol was available in 7256 WHI women across race.

Table 2. Study-Specific and Meta-Analysis Findings in White Individuals for the Association of rs10757278 (9p21 Locus) With Incident Coronary Heart Disease Using Different Event Definitions

Models	SNP	Coded/Other		Study	Events	Total No.	MAF	HR	95% CI	P	I ² (P)
		Allele									
Model 1‡	rs10757278	G/A		ARIC	1453	10 247	0.48	1.14	1.06, 1.23	0.0003	
				CHS	1173	3978	0.49	1.10	1.01, 1.19	0.02	
				WHI	4000	12 392	0.50	1.22	1.18, 1.25	2.5×10 ⁻⁴⁰	
				Combined§	6626	26 617		1.19	1.16, 1.23	4.7×10 ⁻⁴¹	71.5% (0.03)
Model 2†	rs10757278			ARIC	864	10 247	0.48	1.14	1.04, 1.25	0.006	
				CHS	821	3978	0.49	1.11	1.01, 1.22	0.03	
				WHI	3578	12 393	0.50	1.15	1.10, 1.20	3.2×10 ⁻¹¹	
				Combined§	5263	26 618		1.14	1.10, 1.18	4.5×10 ⁻¹³	0.0% (0.79)

SNP indicates single nucleotide polymorphism; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval. For study abbreviations see text.

*In Model 1, an event was defined as nonfatal acute myocardial infarct (MI), fatal coronary heart disease (CHD), and coronary revascularization procedures (coronary angioplasty or coronary artery bypass graft).

†In Model 2, an event was defined as nonfatal acute MI and fatal CHD. Both models were adjusted for age, sex (except WHI), site, or region and population stratification.

‡HR 1.21, 95% CI 1.17, 1.24 for model adjusted for age, sex (except WHI), site or region, body mass index (BMI), ever smoking, type 2 diabetes, systolic blood pressure, anti-hypertensive medication use, education (12 y or equivalent vs less 12 y), HDL and LDL (except WHI where lipids were available in only a subset of the sample, see Table 1) and population stratification.

§Meta-analyses using fixed effect models.

although large heterogeneity remained across age strata (Figure 1A, online-only Data Supplement Table IV). In sex-specific analysis, the CHD hazard was greater in women compared with in men, with large between-sex heterogeneity of effects (Figure 1B; online-only Data Supplement Table V). In analyses stratified by age and sex, the risk of CHD was greater in women than in men at earlier ages (Figure 1C; online-only Data Supplement Table VI). To investigate CHD phenotypic heterogeneity caused by inclusion of revascularization procedures, we performed sensitivity analyses using only nonfatal MI and CHD fatal events. Between-study heterogeneity for the CHD associations of rs10757278 was no longer present in

these analyses (Table 2). Online-only Data Supplement Table VII, shows the findings using this definition for additional loci showing heterogeneity.

We also examined whether SNP associations with CHD generalize to samples of US minority groups (Table 5). Because of high correlation between the SNPs in the 9p21 region in black individuals and SHS American Indian participants (online-only Data Supplement Figure S1A-D, <http://stroke.ahajournals.org>), we only report findings for rs10757278. The association of rs10757278 with incident CHD did not replicate in black participants despite large sample sizes and greater than 80% power to detect an

Table 3. Replication of Associations in White Individuals for Additional Coronary Heart Disease Loci

SNP	Gene/Region	Coded/Other Allele	Study	Coded Allele Frequency	Event	Total No.	HR	95% CI	P	P-hetero	I ²
rs599839	<i>CELSR2-SORT1*</i>	A/G	CHS-WHI	0.77	4965	16 367	1.02	0.98, 1.05	0.37	0.27	18.7%
rs2549513	16q23.1	A/C	CHS-WHI	0.86 to 0.87	4746	15 658	1.08	1.04, 1.13	0.0004	0.87	0.0%
rs499818	6p25.1	A/G	CHS-WHI	0.25	4962	15 718	1.06	1.03, 1.10	0.0002	0.74	0.0%
rs6922269	<i>MTHFD1L*</i>	A/G	WHI	0.26	3995	12 394	1.11	1.07, 1.15	5.1×10 ⁻¹⁰		
rs2943634	2q36.3*	C/A	WHI	0.67	3963	12 316	1.07	1.04, 1.11	6.7×10 ⁻⁶		
rs17465637	<i>MIA3*</i>	C/A	WHI	0.72	4003	12 408	1.01	0.98, 1.04	0.63		
rs17228212	<i>SMAD3*</i>	T/C	WHI	0.72	4003	12 404	0.97	0.94, 1.00	0.09		
rs429358	<i>APOE†</i>	C/T	WHI	0.13	3969	12 313	1.20	1.15, 1.25	2.7×10 ⁻¹⁸		
rs4804611	<i>ZNF627</i>	A/G	WHI-CHS	0.73	4485	15 536	1.09	1.06, 1.13	5.0×10 ⁻⁸	0.45	0.0%
rs501120	<i>CXCL12</i>	A/G	WHI-CHS	0.86	5117	15 591	1.10	1.06, 1.15	1.4×10 ⁻⁶	0.05	74.7%
rs268	<i>LPL</i>	G/A	WHI	0.02	4004	12 408	1.46	1.34, 1.60	2.7×10 ⁻¹⁷		
rs11206510	<i>PCSK9</i>	T/C	ARIC-WHI-CHS	0.82	6203	25 051	1.00	0.96, 1.03	0.84	0.42	0.0%

Data are either one study estimates or meta-analyses of multiple listed studies.

SNP indicates single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; P-hetero, P values for between-study heterogeneity; CHS, Cardiovascular Health Study; WHI, Women's Health Initiative; ARIC, Atherosclerosis Risk in Communities.

*These SNP associations with incident CHD have been previously published in ARIC and therefore ARIC estimates are not included in the analyses (but included in online-only Data Supplement Table II). For WHI, estimates were weighted based on sampling.

†For rs7412, C allele-coded, HR, 1.14; 95% CI, 1.08, 1.21; P, 2.4×10⁻⁶; N, 12 312, events, 3979.

Table 4. Additive Genetic Score Comprised of Eight Significant Single Nucleotide Polymorphisms and the Risk of Incident Coronary Heart Disease in White Individuals

Risk Score Categories	Total No.	Events	HR	95% CI	P
(0,5)	645	187	1.0		
(6,7)	3722	1136	1.15	1.03, 1.28	0.02
(8,9)	5615	1806	1.50	1.35, 1.67	1.7×10^{-13}
(10,16)	2143	757	1.91	1.71, 2.14	2.2×10^{-29}
Continuous	12 125	3886	1.13	1.12, 1.15	4.4×10^{-77}

The following SNPs (coded allele) were included in the risk score: rs10757278 (G), rs2549513(A), rs499818(A), rs6922269(A), rs429358(C), rs4804611(A), rs501120(T), rs268(G) and rs2943634(C).

HR indicates hazard ratio; CI, confidence interval.

effect of similar magnitude to white individuals (Table 5). SNPs in the 9p21 region were nominally associated with CHD in American Indian individuals with similar magnitude and direction of effect as in white individuals. However, we also observed significant between-study heterogeneity of effect across the 4 groups of American Indian participants, as well as in analyses including only SHS participants (Table 5). We were unable to evaluate the associations in the 9p21 region in Hispanic and Asian/Pacific Islander participants because of limited sample sizes. Other loci showing nominal associations in minorities are shown in Table 5.

Discussion

Replication of the association of SNPs in the 9p21 region with incident CHD was found in white individuals, as well as generalization of these associations to American Indian individuals but not to black, Hispanic, or Asian/Pacific Islander individuals. Our study size was limited for Hispanic and Asian participants, but previous studies have shown associations of this region with CHD in Pakistani individuals (1851 MI cases and 1903 controls),³⁷ Han Chinese individuals (510 CHD cases and 557 controls),³⁸ Japanese and Korean individuals^{39,40} and US Hispanic individuals (82 cases and 108 controls).³ This locus has been recently shown to disrupt a transcription-factor-binding site involved in the inflammatory response (STAT1), which affects the expression of the *CDKN2A-2B* genes.⁴¹ Consistent with previous reports, we identified age- and sex-specific effects for the 9p21 locus on CHD risk. The rs10757278 G risk variant showed a larger effect in younger compared with older cohort participants, more evident for individuals age 55 years or younger and in women. Heterogeneity in the estimates for 9p21 in white individuals persisted even after adjusting for multiple risk factors for CHD, but was no longer present in analyses that excluded revascularization procedures from the definition of incident CHD events. Because the use of CHD revascularization procedures (coronary angioplasty or coronary artery bypass graft) may vary in subgroups of individuals because of indication (younger symptomatic individuals and men are more likely to be offered procedures) and to socioeconomic factors (access to care), our results highlight the importance of using strict and homogeneous definition of CHD events

when combining data from multiple studies for evaluation of genetic effects. Thus, our results do not support sex- and age-specific effects for 9p21 locus for incident CHD.

We were able to replicate multiple other loci in white individuals including *MTHFD1L*, 16q23.1, 6p24.1, 2q36.3, *APOE*, *ZNF627*, *CXCL12*, and *LPL*. Most of these loci were initially identified in the Wellcome Trust Case Control Consortium (WTCCC).²⁴ In general, we noticed a modestly greater CHD risk in our prospective analysis compared with the magnitude of association described using a case-control design in previous studies.^{24,28,42} However, the risk score using these variants showed consistent graded increased CHD risk. In addition, we found significant between-study heterogeneity for the *MTHFD1L* and *CXCL12* loci (online-only Data Supplement Table II), similar to findings recently described in the case-control meta-analysis of the Coronary ARtery DIsease Genome-wide Replication And Meta-Analysis (CARDIoGRAM) consortium for the *MTHFD1L* associations.⁴²

The direction of effect of the remaining SNPs evaluated in white individuals was consistent with those in the discovery studies. Interestingly, 3 loci—*CELSR2/SORT1*, *MIA3* and *PCSK9*—which have been associated with early-onset MI in whites,²⁸ did not replicate in our study and in a recently published study of Finland and Sweden individuals.⁴³ Recent experimental evidence suggests a role of *SORT1* product, sortilin 1, in the hepatic metabolism of lipoproteins containing apolipoprotein B.⁴⁴ We had over 80% power to detect an effect for this locus in white individuals, assuming effects similar in magnitude to those published. Because our incident cases were first CHD events occurring after age 45 years and the studies that identified these SNPs were cases of early MI compared with controls, our negative findings are not inconsistent with the previously reported associations in white individuals.

None of the SNPs tested were significantly associated with CHD in black participants after adjustments for multiple testing and our samples in Hispanic and Asian participants were limited preventing conclusions. SNPs in the 9p21 region available for this analysis are highly correlated ($r^2 > 0.85$) in black individuals. However, the genotyped SNPs may not be ideal proxy for functional SNPs in the region for populations of recent African ancestry. In addition, 3 other well-powered SNP associations (rs599839, rs6922269, and rs2943634) were not significant in black participants. Testing additional SNPs at these and other loci may help to elucidate whether LD patterns account for some of the negative findings in black participants.

The strengths of this study are the prospective evaluation of the genetic effect on CHD risk in large population-based studies and the multiethnic evaluation of CHD loci. Our analyses were limited to SNPs previously identified in individuals of European ancestry, reported by January 2009, when SNP selection was performed for genotyping in PAGE. Therefore, we did not evaluate recently discovered variants, and we were unable to evaluate race-specific




Figure. A-C, Meta-analysis results of the association of rs10757278 9p21 variant by age of study recruitment (**A**), sex (**B**), and age and sex strata (**C**).

Table 5. Associations of Coronary Heart Disease Loci in US Minorities

SNP/Gene	Race/ Ethnicity	Coded/Other Allele	Studies	Event	Total No.	Coded Allele Frequency	HR	95% CI	<i>P</i>	<i>I</i> ² (<i>P</i> -hetero)	Power‡
rs10757278 (9p21)	African American	G/A	ARIC-CHS-WHI	914	8018	0.20–0.23	0.94	0.85, 1.04	0.22	73.9% (0.02)	0.82
	American Indian		SHS-WHI†	595	3669	0.43–0.45	1.15	1.03, 1.29	0.02	83.7% (0.002)	0.84
	Hispanic		WHI	113	1903	0.47	1.17	0.97, 1.41	0.11		0.22
	Asian/Pacific Islander		WHI	66	885	0.51	1.50	1.19, 1.89	0.0005		0.14
rs599839 (<i>CELSR2</i>)	African American	A/G	ARIC-CHS-WHI	838	7211	0.26–0.31	1.04	0.96, 1.14	0.35	0.0% (0.40)	0.89
	American Indian		SHS-WHI†	596	3659	0.17–0.33	1.14	0.99, 1.31	0.08	18.1% (0.30)	0.72
	Hispanic		WHI	112	1888	0.25	1.03	0.83, 1.29	0.76		0.17
	Asian/Pacific Islander		WHI	66	885	0.08	0.72	0.51, 1.03	0.07		0.08
rs2549513 (16q23.1)	African American	A/C	CHS-WHI	485	4559	0.75	0.98	0.87, 1.10	0.70	0.0% (0.92)	0.58
	American Indian		WHI	20	203	0.88	0.93	0.49, 1.80	0.04		0.06
	Hispanic		WHI	113	1905	0.90	1.00	0.73, 1.37	1.0		0.12
	Asian/Pacific Islander		WHI	66	886	0.93	2.77	1.33, 5.77	0.007		0.08
rs499818 (6p25.1)	African American	A/G	CHS-WHI	485	4565	0.13	1.09	0.95, 1.26	0.23	52.2% (0.15)	0.43
	American Indian		WHI	20	203	0.30	0.94	0.57, 1.55	0.81		0.07
	Hispanic		WHI	113	1903	0.30	0.77	0.61, 0.96	0.02		0.22
	Asian/Pacific Islander		WHI	66	884	0.12	1.31	0.95, 1.81	0.11		0.10
rs6922269 (<i>MTHFD1L</i>)	African American	A/G	ARIC-WHI	682	6523	0.54	1.03	0.95, 1.13	0.46	0.0% (0.48)	0.82
	American Indian		WHI	20	203	0.34	0.76	0.47, 1.23	0.27		0.07
	Hispanic		WHI	112	1904	0.36	1.16	0.96, 1.42	0.13		0.23
	Asian/Pacific Islander		WHI	66	885	0.04	0.34	0.11, 1.02	0.06		0.07
rs2943634 (2q36.3)	African American	C/A	ARIC-WHI	677	6502	0.41–0.43	1.02	0.93, 1.12	0.68	0.0% (0.98)	0.81
	American Indian		WHI	20	203	0.71	1.29	0.76, 2.16	0.34		0.07
	Hispanic		WHI	113	1897	0.75	0.95	0.76, 1.18	0.64		0.19
	Asian/Pacific Islander		WHI	65	883	0.90	2.00	1.20, 3.33	0.008		0.08
rs17465637 (<i>MIA3</i>)	African American	C/A	ARIC-WHI	681	6514	0.25–0.28	1.06	0.96, 1.17	0.23	0.0% (0.99)	0.47
	American Indian		WHI	20	203	0.59	1.49	0.96, 2.30	0.07		0.07
	Hispanic		WHI	113	1905	0.55	0.91	0.76, 1.09	0.31		0.24
	Asian/Pacific Islander		WHI	66	886	0.57	0.85	0.67, 1.07	0.17		0.15
rs17228212 (<i>SMAD3</i>)*	African American	T/C	ARIC-WHI	683	6526	0.87	0.87	0.77, 0.99	0.03	63.5% (0.10)	0.51

(Continued)

Table 5. Continued

SNP/Gene	Race/ Ethnicity	Coded/Other Allele	Studies	Event	Total No.	Coded Allele Frequency	HR	95% CI	<i>P</i>	<i>I</i> ² (<i>P</i> -hetero)	Power‡
rs429358 (<i>APOE</i>)	American Indian	C/T	WHI	20	203	0.80	1.54	0.86, 2.76	0.15		0.07
	Hispanic		WHI	113	1904	0.83	0.75	0.59, 0.95	0.02		0.16
	African American		WHI	376	3930	0.20	1.06	0.93, 1.21	0.35		0.41
	American Indian		WHI	20	201	0.14	0.50	0.22, 1.15	0.10		0.06
	Hispanic		WHI	112	1892	0.12	1.04	0.77, 1.39	0.81		0.10
	Asian/Pacific Islander		WHI	65	880	0.10	1.04	0.71, 1.52	0.83		0.07
rs4804611 (<i>ZNF627</i>)	African American	A/G	CHS-WHI	561	4557	0.82	1.05	0.93, 1.19	0.41	0.0% (0.75)	0.99
	American Indian		WHI	20	203	0.75	1.50	0.87, 2.61	0.15		0.44
	Hispanic		WHI	113	1905	0.72	0.91	0.74, 1.11	0.33		0.99
	Asian/Pacific Islander		WHI	66	886	0.72	0.78	0.56, 1.09	0.14		0.98
rs501120 (<i>CXCL12</i>)	African American	A/G	CHS-WHI	566	4547	0.60	1.10	0.97, 1.21	0.06	55.1% (0.14)	0.54
	American Indian		WHI	20	203	0.77	1.87	0.92, 3.83	0.09		0.07
	Hispanic		WHI	113	1904	0.75	1.00	0.80, 1.24	1.00		0.20
	Asian/Pacific Islander		WHI	66	885	0.67	1.20	0.93, 1.54	0.15		0.15
rs11206510 (<i>PCSK9</i>)	African American	T/C	ARIC-CHS-WHI	818	7168	0.86	0.99	0.88, 1.12	0.88	0.0% (0.41)	0.99
	American Indian		SHS	576	3472	0.95–0.99	1.10	0.80, 1.52	0.56	0.0% (0.85)	0.18–0.62
	Hispanic			113	1904	0.86	1.06	0.80, 1.40	0.70		0.81
	Asian/Pacific Islander			66	886	0.95	0.83	0.53, 1.29	0.41		0.22

Data are either single-study estimates or combined estimates from meta-analyses of multiple listed studies.

SNP indicates single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; *P*-hetero, *P* values for between-study heterogeneity; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; WHI, Women’s Health Initiative.

*Estimates not reported in Asian/Pacific Islanders due to MAF=0.006. LPL SNP estimates not reported due to low MAF (0.003 in African Americans, 0.007 in Hispanics, 0.0005 in Asian/Pacific Islanders and 0.01 in American Indians).

†Results were unchanged in meta-analysis excluding WHI American Indians.

‡Power was estimated assuming an additive genetic effect, effect estimate size of associations in white individuals, an alpha=0.05, MAF of the target population, a two-sided test and population risk of 0.10. For rs599839 and rs499818, effect size is not available so we used estimates of 1.20.

variants in these loci that will require fine mapping of the regions.

In summary, we identified significant heterogeneity of the 9p21 locus and other loci in individuals of European ancestry in prospective analyses of CHD risk, some of which could be explained by differences in event definition. Overall, some SNP associations replicated in longitudinal analysis of white individuals, but effects were modest; also, none of the SNPs were associated with incident CHD in large sample sizes of black participants. Fine mapping of these regions may help to clarify these negative findings.

Acknowledgements

The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions.

Sources of Funding

The PAGE program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo), U01HG004798 (EAGLE), U01HG004802 (MEC), U01HG004790 (WHI), and U01HG004801 (Coordinating Center). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. The complete list of PAGE members can be found at <http://www.pagestudy.org>.

The data and materials included in this report result from collaborations between the following studies. Funding support for the Epidemiology of Putative Genuine Genetic Variants: The Women’s Health Initiative study is provided through the NHGRI PAGE program (U01HG004790). The WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; and US Department of Health and Human Services through contracts N01WH22110, 24152, 32100 to 32102, 32105 to 32106, 32108 to 32109, 32111 to 32113, 32115, 32118 to 32119, 32122,

42107 to 42126, 42129 to 42132, and 44221. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whiscience.org/publications/WHI_investigators_shortlist.pdf.

Funding support for the CALiCo program was provided through the NHGRI PAGE program (U01HG004803). The following studies contributed to this manuscript and are funded by the following agencies: The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The CARDIA study is supported by the following National Institutes of Health and National Heart, Lung and Blood Institute contracts: N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, and N01-HC-45205. The CHS is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, grants U01HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. CHS GWAS DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The SHS is supported by NHLBI grants U01 HL65520, U01 HL41642, U01 HL41652, U01 HL41654, and U01 HL65521. The opinions expressed in this article are those of the author(s) and do not necessarily reflect the views of the Indian Health Service.

Assistance with phenotype harmonization, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by the PAGE Coordinating Center (U01HG004801-01). The National Institutes of Mental Health also contributes to the support for the Coordinating Center.

Disclosures

None.

References

- Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. *Nature*. 2010;464:409-412.
- McPherson R, Pertsemlidis A, Kavassari N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. *Science*. 2007;316:1488-1491.
- Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. *Hum Mol Genet*. 2008;17:2320-2328.
- Matarin M, Brown WM, Singleton A, Hardy JA, Meschia JF. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. *Stroke*. 2008;39:1586-1589.
- Yamagishi K, Folsom AR, Rosamond WD, Boerwinkle E. A genetic variant on chromosome 9p21 and incident heart failure in the ARIC study. *Eur Heart J*. 2009;30:1222-1228.
- Cluett C, McDermott MM, Guralnik J, Ferrucci L, Bandinelli S, Miljkovic I, Zmuda JM, Li R, Tranah G, Harris T, Rice N, Henley W, Frayling TM, Murray A, Melzer D. The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. *Circ Cardiovasc Genet*. 2009;2:347-353.
- Helgadóttir A, Thorleifsson G, Magnusson KP, Grétarsdóttir S, Steinthorsdóttir V, Manolescu A, Jones GT, Rinkel GJ, Blankenstein JD, Ronkainen A, Jaaskelainen JE, Kyo Y, Lenk GM, Sakalihan N, Kostulas K, Gottsater A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsson E, Walters GB, Jonsdóttir T, Snorráðóttir S, Magnúsdóttir D, Gudmundsson G, Ferrell RE, Sveinbjórnsson S, Hernesniemi J, Niemela M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, Tejjink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadóttir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thorgeriðsson G, Kong A, Thorsteinsdóttir U, Stefansson K. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. *Nat Genet*. 2008;40:217-224.
- Helgadóttir A, Thorleifsson G, Manolescu A, Gretarsdóttir S, Blondal T, Jonasdóttir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasson SE, Jonsdóttir T, Palsson S, Einarsdóttir H, Gunnarsdóttir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeriðsson G, Thorsteinsdóttir U, Kong A, Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*. 2007;316:1491-1493.
- Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. *Jama*. 2010;303:648-656.
- Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities study. *Am J Epidemiol*. 2010;171:14-23.
- Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet*. 2008;40:161-169.
- Kathiresan S, Melander O, Anevski D, Guiducci C, Burt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N Engl J Med*. 2008;358:1240-1249.
- Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllenstein U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet*. 2009;41:47-55.
- Statistics. NCFH. Plan and operation of the third national health and nutrition examination survey, 1988-94 1994.
- Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol*. 2000;151:346-357.
- Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. *Control Clin Trials*. 1998;19:61-109.
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. The aric investigators. *Am J Epidemiol*. 1989;129:687-702.
- Hughes GH, Cutter G, Donahue R, Friedman GD, Hulley S, Hunkeler E, Jacobs DR, Jr., Liu K, Orden S, Pirie P. Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study. *Control Clin Trials*. 1987;8:68S-73S.

19. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol.* 1991;1:263–276.
20. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV. The strong heart study. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. *Am J Epidemiol.* 1990;132:1141–1155.
21. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, MacCluer JW. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. *Am J Epidemiol.* 2003;157:303–314.
22. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. *Ann Epidemiol.* 2003;13:S122–S128.
23. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007;447:661–678.
24. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, König IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. *N Engl J Med.* 2007;357:443–453.
25. Larson MG, Atwood LD, Benjamin EJ, Cupples LA, D'Agostino RB, Sr., Fox CS, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Murabito JM, Newton-Cheh C, O'Donnell CJ, Seshadri S, Vasani RS, Wang TJ, Wolf PA, Levy D. Framingham heart study 100k project: Genome-wide associations for cardiovascular disease outcomes. *BMC Med Genet.* 2007;8 Suppl 1:S5.
26. Sahoo GS, Tatt I, Salanti G, Butterworth AS, Sarwar N, van Maarle M, Jukema JW, Wiman B, Kastelein JJ, Bennet AM, de Faire U, Danesh J, Higgins JP. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. *Am J Epidemiol.* 2008;168:1233–1246.
27. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. *Ann Intern Med.* 2004;141:137–147.
28. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardisino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Giarelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Merlino PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Feteveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonin P, Piazza A, Yee J, Friedlander Y, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Meigs JB, Williams G, Nathan DM, MacRae CA, Havulinna AS, Berglund G, Hirschhorn JN, Asselta R, Duga S, Sreafico M, Daly MJ, Nemes J, Korn JM, McCarroll SA, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burt N, Gabriel SB, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS, Linsel-Nitschke P, Lieb W, Ziegler A, König I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Ouwehand W, Deloukas P, Scholz M, Cambien F, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Scheffold T, Berger K, Hogue A, Martinelli N, Olivieri O, Corrocher R, McKeown P, Erdmann E, König IR, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Do R, Xie C, Siscovick D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet.* 2009;41:334–341.
29. Zondervan KT, Cardon LR. The complex interplay among factors that influence allelic association. *Nat Rev Genet.* 2004;5:89–100.
30. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet.* 2009;2:73–80.
31. Breslow NE. Discussion of professor cox's paper. *J Royal Stat Soc B.* 1972;34:216–217.
32. Kitsios GD, Dahabreh IJ, Trikalinos TA, Schmid CH, Huggins GS, Kent DM. Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies. *Circ Cardiovasc Genet.* 2011;4:58–67.
33. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O'Brien SJ, Altshuler D, Daly MJ, Reich D. Methods for high-density admixture mapping of disease genes. *Am J Hum Genet.* 2004;74:979–1000.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177–188.
35. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations. *PLoS ONE.* 2007;2:e841.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557–560.
37. Saleheen D, Alexander M, Rasheed A, Wormser D, Soranzo N, Hammond N, Butterworth A, Zaidi M, Haycock P, Bumpstead S, Potter S, Blackburn H, Gray E, Di Angelantonio E, Kaptoge S, Shah N, Samuel M, Janjua A, Sheikh N, Haider SR, Murtaza M, Ahmad U, Hakeem A, Memon MA, Mallick NH, Azhar M, Samad A, Rasheed SZ, Gardezi AR, Memon NA, Ghaffar A, Fazal Ur R, Zaman KS, Kundi A, Yaqoob Z, Cheema LA, Qamar N, Faruqi A, Joorna R, Niazi JH, Hussain M, Kumar K, Saleem A, Daood MS, Memon F, Gul AA, Abbas S, Zafar J, Shahid F, Memon Z, Bhatti SM, Kayani W, Ali SS, Fahim M, Ishaq M, Frossard P, Deloukas P, Danesh J. Association of the 9p21.3 locus with risk of first-ever myocardial infarction in Pakistanis: case-control study in South Asia and updated meta-analysis of Europeans. *Arterioscler Thromb Vasc Biol.* 2010;30:1467–1473.
38. Ding H, Xu Y, Wang X, Wang Q, Zhang L, Tu Y, Yan J, Wang W, Hui R, Wang CY, Wang DW. 9p21 is a shared susceptibility locus strongly for coronary artery disease and weakly for ischemic stroke in Chinese Han population. *Circ Cardiovasc Genet.* 2009;2:338–346.
39. Hiura Y, Fukushima Y, Yuno M, Sawamura H, Kokubo Y, Okamura T, Tomoike H, Goto Y, Nonogi H, Takahashi R, Iwai N. Validation of the association of genetic variants on chromosome 9p21 and 1q41 with myocardial infarction in a Japanese population. *Circ J.* 2008;72:1213–1217.
40. Hinohara K, Nakajima T, Takahashi M, Hohda S, Sasaoka T, Nakahara K, Chida K, Sawabe M, Arimura T, Sato A, Lee BS, Ban JM, Yasunami M, Park JE, Izumi T, Kimura A. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. *J Hum Genet.* 2008;53:357–359.
41. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, Frazer KA. 9p21 DNA variants associated with coronary artery disease impair interferon- γ signalling response. *Nature.* 2011;470:264–268.
42. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardisino D, Ball SG, Balmforth AJ, Barnes TA, Braund DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifer S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Giarelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lette G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlino PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeier J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43:333–338.
43. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. A

multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. *Lancet*. 2010;376:1393–1400.

44. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser N, Ruda VM, Pirruccello JP, Muchmore B, Prokunina-Olsson L, Hall JL, Schadt EE, Morales CR,

Lund-Katz S, Phillips MC, Wong J, Cantley W, Racie T, Ejebe KG, Orho-Melander M, Melander O, Koteliansky V, Fitzgerald K, Krauss RM, Cowan CA, Kathiresan S, Rader DJ. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature*. 2010;466:714–719.

CLINICAL PERSPECTIVE

This study investigated the association of reported genome-wide, cross-sectional coronary heart disease (CHD) single nucleotide polymorphisms (SNPs) with incident CHD. We replicated 9 CHD loci in individuals of European ancestry, including 9p21, 16q23.1, 6p24.1, 2q36.3, *MTHFDIL*, *APOE*, *ZNF627*, *CXCL12*, and *LPL*. The inclusion of coronary revascularization procedures among the incident CHD events introduced heterogeneity; for example, a 9p21 variant showed larger genetic effects in individuals age 55 years or younger and in women. The SNPs were not associated with CHD in black individuals and associations varied in other US minorities. Fine mapping of these regions may help to clarify these negative findings.